Início › Mieloma Múltiplo › Carolina do Norte › Durham
Ensaios clínicos de Mieloma Múltiplo em Durham, NC
37 estudos para Mieloma Múltiplo estão buscando participantes em locais em Durham e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecrutandoFase 3
- Research Site, Chapel Hill · a 10 mi de distância
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RecrutandoFase 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · a 10 mi de distância
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecrutandoFase 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
RecrutandoFase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · a 10 mi de distância
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecrutandoFase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecrutandoFase 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 2
- University of North Carolina Medical Center, Chapel Hill · a 10 mi de distância
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RecrutandoFase 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · a 10 mi de distância
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
RecrutandoFase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · a 13 mi de distância
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RecrutandoFase 1/2
- GSK Investigational Site, Chapel Hill · a 10 mi de distância
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RecrutandoFase 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecrutandoFase 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecrutandoFase 3
- Research Site, Durham
- Research Site, Chapel Hill · a 10 mi de distância
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Recrutando
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · a 10 mi de distância
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RecrutandoFase 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RecrutandoFase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · a 10 mi de distância
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RecrutandoFase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · a 10 mi de distância
Selinexor and Backbone Treatments of Multiple Myeloma Patients
RecrutandoFase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 1
- University of North Carolina /ID# 251203, Chapel Hill · a 10 mi de distância
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RecrutandoFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
RecrutandoFase 2
- University of North Carolina (Data Collection Only), Chapel Hill · a 10 mi de distância
Registry of Older Patients With Cancer
RecrutandoEstudo observacional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi de distância
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RecrutandoFase 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RecrutandoFase 2
- University of North Carolina, Chapel Hill · a 10 mi de distância
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RecrutandoFase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RecrutandoFase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · a 10 mi de distância
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RecrutandoFase 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · a 13 mi de distância
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecrutandoFase 1
- University of North Carolina, Chapel Hill · a 10 mi de distância
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RecrutandoFase 1
- University of North Carolina, Chapel Hill · a 10 mi de distância
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecrutandoFase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · a 10 mi de distância
Registry for Adults With Plasma Cell Disorders (PCD's)
RecrutandoEstudo observacional
- North Carolina Cancer Hospital, Chapel Hill · a 10 mi de distância
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecrutandoEstudo observacional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi de distância
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RecrutandoFase 1
- Duke University Health System (DUHS), Durham
Ensaios de Mieloma Múltiplo em outras cidades
- New York City, NY60 estudos
- Boston, MA42 estudos
- Atlanta, GA41 estudos
- Houston, TX38 estudos
- Nashville, TN32 estudos
- Denver, CO27 estudos
- Rochester, MN24 estudos
- St. Louis, MO24 estudos
- Columbus, OH24 estudos
- Baldwin Park, CA23 estudos
- Chicago, IL22 estudos
- Seattle, WA22 estudos
Outros estudos em Durham
- Câncer de Mama63 estudos
- Câncer (todos os tipos)58 estudos
- Câncer de Pulmão de Não Pequenas Células39 estudos
- Câncer Metastático33 estudos
- Leucemia Mieloide Aguda33 estudos
- Câncer de Pulmão32 estudos
- Câncer de Próstata32 estudos
- Câncer Colorretal28 estudos
- Leucemia Linfocítica Crônica27 estudos
- Câncer de Ovário27 estudos
- Insuficiência Cardíaca26 estudos
- Câncer de Pâncreas24 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.